We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Apogee Therapeutics, Inc. (NASDAQ:APGE) stands against the other small-cap stocks.
The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year post-COVID. With the index hitting all-time highs, small-cap stocks can be a good option to explore with higher growth potential in the long term.
However, the Russell 2000 small-cap index returned a little over 7% in 2024 compared to the 23% returns by the S&P 500. Over the past five years (through February 25, 2025), the S&P 500 has almost doubled the return of the Russell 2000 small cap, with returns of 102% against 47%, respectively.
Small-Cap Stocks Prospects in 2025
On December 30, MJP Wealth Advisors chief investment officer Brian Vendig appeared on Yahoo! Finance’s Catalysts to address the potential outlook of small-cap stocks in 2025. Vendig said that a stable economy and policy will positively impact the small-caps, creating business expansion and merger opportunities. However, the Trump administration’s harsh tariff policies could impact the broader small-cap stocks as these companies contribute significantly to the U.S. domestic market.
The role of the Fed will also be key in keeping the economy afloat. Vendig said that the market is expected to be choppy in the first few months of 2025. Businesses will start to progress in the second half of 2025 as the policies become clearer. However, Vendig believed that if earnings remain intact, he will likely stay constructive on stocks. He is also bullish on bonds, which might be a good opportunity as well. He said:
“I’m definitely not one to recommend adding to mega-cap tech at this point, but I think taking a look at some of those value-oriented sectors that help to play into innovation and growth for the economy still makes sense.”
With that said, let’s take a look at the Best Small-Cap Stock to Buy Now.
A biotechnology research center with scientists wearing lab coats and goggles experimenting with single molecule sequencing.
Our Methodology
We used the Finviz stock screener to compile a list of 30 small-cap stocks. We then selected the top 10 best small-cap stocks based on hedge fund sentiment as of Q4 2024. We have used analyst upside, as of February 27, as a secondary metric to rank the stocks with the same number of hedge fund holders. The list is sorted in ascending order of number of hedge fund holders.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Apogee Therapeutics, Inc. (NASDAQ:APGE)
Analyst Upside: 164.49%
No. of Hedge Fund Holders: 31
Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company engaged in treating immunological and inflammatory diseases. The company has a wide portfolio and it has the potential to treat various dermatological, respiratory, and gastroenterological conditions. Apogee is making developments in the trials for key drugs, participating in crucial conferences, and revealing important updates from trials.
On February 3, the company reported that the first patient was dosed in the Part B portion of Phase 2 of its clinical trial of APG777 in patients with moderate-to-severe AD. The company has also completed the enrollment of the same phase in the Part A portion of the trial. The Chief Medical Officer of Apogee, Carl Dambkowski, addressed the accelerated development of its APG777 trails and said:
“Enrollment for the Phase 2 Part A trial of APG777 surpassed the approximately 110 patient target ahead of schedule, driven by strong patient and investigator enthusiasm, underscoring the potential of APG777 to address the need for safe, effective treatment options that reduce injection burden and provide better disease control for patients with AD and other I&I conditions.”
During Q3 2024, Apogee Therapeutics, Inc. (NASDAQ:APGE) management mentioned that they are on track to release Phase 2 Part A data for APG777 in the second half of 2025. The company is also progressing on its APG333 trials, which have the potential to offer top-notch efficacy across several respiratory conditions, representing a solid feat for Apogee’s growth potential. By the end of Q3, the company had around $754 million in cash and cash equivalents, addressing its ability to operate smoothly into 2028. APGE is one of the emerging players in the biotech industry and the company plans to continue building its portfolio with transformative therapies.
Overall, APGE ranks 9th on our list of best small-cap stocks to buy now. While we acknowledge the potential of APGE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than APGE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
